{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Abaloparatide",
    "short_name": "Abaloparatide",
    "aliases": [],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "status": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-20",
      "human_use_note": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "title": "What it is",
          "text": "Abaloparatide is a synthetic peptide that activates the parathyroid hormone receptor pathway and is used as a prescription treatment for osteoporosis in specific high-risk patients."
        },
        {
          "title": "What people use it for in practice",
          "text": "In legitimate use, it’s a clinician-directed osteoporosis therapy aimed at lowering fracture risk. It’s not a general wellness compound and isn’t a fit for self-directed experimentation."
        }
      ],
      "use_cases": [
        {
          "title": "Intended use context",
          "text": "This is primarily a medical osteoporosis therapy. Pep-Talk does not provide dosing or protocols."
        }
      ],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-20",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Abaloparatide",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "abaloparatide"
  },
  "interactions": {
    "drug_classes": [],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "Abaloparatide is a prescription osteoporosis medicine used to reduce fracture risk in high-risk patients. Outside of supervised medical care, the main real-world risk is using a potent bone-active drug without appropriate evaluation and monitoring.",
    "benefits": [
      "Lower fracture risk in indicated high-risk osteoporosis patients (medical use)",
      "Increases bone mineral density over time (medical use)"
    ],
    "side_effects_common": [
      "Dizziness or feeling light-headed (especially early on)",
      "Nausea or stomach upset",
      "Headache",
      "Palpitations / fast heart rate",
      "Injection-site irritation"
    ],
    "side_effects_serious": [
      "Fainting or severe dizziness",
      "Chest pain, severe palpitations, or shortness of breath",
      "Signs of high calcium (confusion, severe constipation, vomiting, weakness)"
    ],
    "who_should_be_cautious": [
      "Anyone with unexplained high calcium or disorders of calcium metabolism",
      "People with prior skeletal radiation therapy or certain bone cancers (contraindication context)",
      "Pregnant or breastfeeding individuals",
      "Adolescents / still-developing skeleton (not an appropriate context)"
    ],
    "schema_version": "practical_block_v1"
  }
}
